ophthalmology

eyeball eye disease eyelash eyes

Biotech

Ocugen’s CEO wants to bring gene therapy to the masses

Many gene therapy outfits focus on technical advances, Ocugen CEO Shankar Musunuri, Ph.D., said, meaning they miss out on broader commercial success.

Darren Incorvaia Apr 16, 2026 9:00am

Closeup of blue eye on black background

Viridian’s Tepezza rival scores ph. 3 win, but investors unsure

Mar 30, 2026 10:11am

Closeup of blue eye on black background

Innovent eyes China approval after matching Eylea in phase 3

Mar 24, 2026 6:00am

Closeup of blue eye on black background

Kalaris pauses eye drug trial to resolve ocular inflammation

Mar 11, 2026 6:30am

Closeup of blue eye on black background

Preclinical eye disease biotech sets sights on $17M NYSE IPO

Feb 18, 2026 8:55am

IPO initial public offering

Agomab, SpyGlass head to Nasdaq with IPOs totaling $350M

Feb 6, 2026 4:04am